Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Authors:
Lauren Wilson1; Zhenxiang Zhao1; Victoria Divino1; Matthew Bassan1; Briain O Hartaigh1; Kerem Ozer1